Cite
Raja K, Daniel N, Morrison S, et al. Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience. J Pharm Pract. 2021;8971900211028208doi: 10.1177/08971900211028208.
Raja, K., Daniel, N., Morrison, S., Patel, R., Gerges, J., Nadeem, K., Chen, B., Kang, S., Patel, M., Beggs, D., Attalla, M., Ballem, N., & Philips, M. (2021). Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience. Journal of pharmacy practice, 8971900211028208. https://doi.org/10.1177/08971900211028208
Raja, Karan, et al. "Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience." Journal of pharmacy practice vol. (2021): 8971900211028208. doi: https://doi.org/10.1177/08971900211028208
Raja K, Daniel N, Morrison S, Patel R, Gerges J, Nadeem K, Chen B, Kang S, Patel M, Beggs D, Attalla M, Ballem N, Philips M. Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience. J Pharm Pract. 2021 Jul 07;8971900211028208. doi: 10.1177/08971900211028208. Epub 2021 Jul 07. PMID: 34231415.
Copy
Download .nbib